193275-84-2 | Lonafarnib

Packsize	Purity	Availability	Price	Discounted Price
1mg	99%	in stock	$22.00	$16.00
5mg	99%	in stock	$77.00	$54.00
10mg	99%	in stock	$113.00	$79.00
25mg	99%	in stock	$182.00	$128.00
50mg	99%	in stock	$301.00	$211.00
100mg	99%	in stock	$466.00	$326.00

Description

• Catalog Number: AE81358
• Chemical Name: Lonafarnib
• CAS Number: 193275-84-2
• Molecular Formula: C27H31Br2ClN4O2
• Molecular Weight: 638.8216
• MDL Number: MFCD06795138
• SMILES: Clc1cc(Br)c2c(c1)CCc1c([C@@H]2C2CCN(CC2)C(=O)CC2CCN(CC2)C(=O)N)ncc(c1)Br
• NSC Number: 719467

Computed Properties

• Complexity: 790
• Covalently-Bonded Unit Count: 1
• Defined Atom Stereocenter Count: 1
• Heavy Atom Count: 36
• Hydrogen Bond Acceptor Count: 3
• Hydrogen Bond Donor Count: 1
• Rotatable Bond Count: 3
• XLogP3: 4.8

Literature

• Targeting protein prenylation in progeria.

  Science translational medicine 20130206

• Farnesyltransferase inhibitors: a comprehensive review based on quantitative structural analysis.

  Current medicinal chemistry 20130101

• Clinical trial of a farnesyltransferase inhibitor in children with Hutchinson-Gilford progeria syndrome.

  Proceedings of the National Academy of Sciences of the United States of America 20121009

• Medicine. Drug trial offers uncertain start in race to save children with progeria.

  Science (New York, N.Y.) 20120928

• A multiplicity of anti-invasive effects of farnesyl transferase inhibitor SCH66336 in human head and neck cancer.

  International journal of cancer 20120801

• Randomized phase II trial of carboplatin and paclitaxel with or without lonafarnib in first-line treatment of epithelial ovarian cancer stage IIB-IV.

  Gynecologic oncology 20120801

• Lonafarnib for cancer and progeria.

  Expert opinion on investigational drugs 20120701

• Targeted therapy for hepatocellular carcinoma: novel agents on the horizon.

  Oncotarget 20120301

• Targeted agents for the treatment of metastatic melanoma.

  OncoTargets and therapy 20120101

• A phase I trial of the farnesyl transferase inhibitor, SCH 66336, with temozolomide for patients with malignant glioma.

  Journal of neuro-oncology 20111201

• Hutchinson-Gilford progeria syndrome with G608G LMNA mutation.

  Journal of Korean medical science 20111201

• A phase I multicenter study of continuous oral administration of lonafarnib (SCH 66336) and intravenous gemcitabine in patients with advanced cancer.

  Cancer investigation 20111101

• Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.

  Cancer 20110901

• Lonafarnib (SCH66336) improves the activity of temozolomide and radiation for orthotopic malignant gliomas.

  Journal of neuro-oncology 20110801

• The farnesyltransferase inhibitors tipifarnib and lonafarnib inhibit cytokines secretion in a cellular model of mevalonate kinase deficiency.

  Pediatric research 20110701

• Progeria, rapamycin and normal aging: recent breakthrough.

  Aging 20110701

• The farnesyl transferase inhibitor lonafarnib inhibits mTOR signaling and enforces sorafenib-induced apoptosis in melanoma cells.

  The Journal of investigative dermatology 20110201

• Phase I and pharmacokinetic study of lonafarnib, SCH 66336, using a 2-week on, 2-week off schedule in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20110201

• Characterization of the in vitro activity of AZD3409, a novel prenyl transferase inhibitor.

  Cancer chemotherapy and pharmacology 20110101

• The role of HDAC6 in cancer.

  Journal of biomedicine & biotechnology 20110101

• Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.

  Current medicinal chemistry 20110101

• Bostrycin inhibits proliferation of human lung carcinoma A549 cells via downregulation of the PI3K/Akt pathway.

  Journal of experimental & clinical cancer research : CR 20110101

• C6-ceramide synergistically potentiates the anti-tumor effects of histone deacetylase inhibitors via AKT dephosphorylation and α-tubulin hyperacetylation both in vitro and in vivo.

  Cell death & disease 20110101

• Critical appraisal of nilotinib in frontline treatment of chronic myeloid leukemia.

  Cancer management and research 20110101

• Microarray-based oncogenic pathway profiling in advanced serous papillary ovarian carcinoma.

  PloS one 20110101

• Hutchinson-Gilford progeria syndrome with severe calcific aortic valve stenosis.

  Annals of pediatric cardiology 20110101

• Ras homologue enriched in brain is a critical target of farnesyltransferase inhibitors in non-small cell lung cancer cells.

  Cancer letters 20101101

• Toward the development of innovative bifunctional agents to induce differentiation and to promote apoptosis in leukemia: clinical candidates and perspectives.

  Journal of medicinal chemistry 20101014

• Novel pyrrolo-1,5-benzoxazepine compounds display significant activity against resistant chronic myeloid leukaemia cells in vitro, in ex vivo patient samples and in vivo.

  British journal of cancer 20100511

• Computer-aided drug design and ADMET predictions for identification and evaluation of novel potential farnesyltransferase inhibitors in cancer therapy.

  Journal of molecular graphics & modelling 20100226

• Targeting the epidermal growth factor receptor in epithelial ovarian cancer: current knowledge and future challenges.

  Journal of oncology 20100101

• Dissecting the roles of DR4, DR5 and c-FLIP in the regulation of geranylgeranyltransferase I inhibition-mediated augmentation of TRAIL-induced apoptosis.

  Molecular cancer 20100101

• Melanoma: Stem cells, sun exposure and hallmarks for carcinogenesis, molecular concepts and future clinical implications.

  Journal of carcinogenesis 20100101

• Dynamics of lamin-A processing following precursor accumulation.

  PloS one 20100101

• Defective lamin A-Rb signaling in Hutchinson-Gilford Progeria Syndrome and reversal by farnesyltransferase inhibition.

  PloS one 20100101

• RNA interference (RNAi) screening approach identifies agents that enhance paclitaxel activity in breast cancer cells.

  Breast cancer research : BCR 20100101

• c-Jun NH2-terminal kinase-dependent upregulation of DR5 mediates cooperative induction of apoptosis by perifosine and TRAIL.

  Molecular cancer 20100101

• Virtual screening and pharmacophore studies for ftase inhibitors using Indian plant anticancer compounds database.

  Bioinformation 20100101

• Design, Synthesis and Evaluation of Novel 1-(Substituted Acetyl)-4-(10-Bromo-8-Chloro-5,6-Dihydro-11H-Benzo[5,6]Cyclohepta[1,2-B]Pyridine-11-Ylidene)piperidines as Antitumor Agents and Farnesyl Protein Transferase Inhibitors.

  Indian journal of pharmaceutical sciences 20100101

• Continuous and intermittent dosing of lonafarnib potentiates the therapeutic efficacy of docetaxel on preclinical human prostate cancer models.

  International journal of cancer 20091201

• [Targeting KRAS pathway in NSCLC therapy].

  Bulletin du cancer 20091201

• Current data and strategy in glioblastoma multiforme.

  Journal of medicine and life 20091115

• Meroterpenes from Dichrostachys cinerea inhibit protein farnesyl transferase activity.

  Journal of natural products 20091001

• A phase II study of Lonafarnib (SCH66336) in patients with chemorefractory, advanced squamous cell carcinoma of the head and neck.

  American journal of clinical oncology 20090601

• Cell cycle effects and increased adduct formation by temozolomide enhance the effect of cytotoxic and targeted agents in lung cancer cell lines.

  Journal of chemotherapy (Florence, Italy) 20090601

• The protein farnesyltransferase regulates HDAC6 activity in a microtubule-dependent manner.

  The Journal of biological chemistry 20090410

• Synergistic apoptosis induction in leukemic cells by the phosphatase inhibitor salubrinal and proteasome inhibitors.

  PloS one 20090101

• Resistance to cisplatin does not affect sensitivity of human ovarian cancer cell lines to mifepristone cytotoxicity.

  Cancer cell international 20090101

• Current available therapies and future directions in the treatment of malignant gliomas.

  Biologics : targets & therapy 20090101

• Managing myelodysplastic symptoms in elderly patients.

  Clinical interventions in aging 20090101

• Farnesyl transferase inhibitor (lonafarnib) in patients with myelodysplastic syndrome or secondary acute myeloid leukaemia: a phase II study.

  Annals of hematology 20081101

• Mass spectrometric studies of potent inhibitors of farnesyl protein transferase--detection of pentameric noncovalent complexes.

  Journal of mass spectrometry : JMS 20081001

• Autophagy induced by farnesyltransferase inhibitors in cancer cells.

  Cancer biology & therapy 20081001

• A phase I safety, pharmacological, and biological study of the farnesyl protein transferase inhibitor, lonafarnib (SCH 663366), in combination with cisplatin and gemcitabine in patients with advanced solid tumors.

  Cancer chemotherapy and pharmacology 20080901

• On the use of lonafarnib in myelodysplastic syndrome and chronic myelomonocytic leukemia.

  Leukemia 20080901

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20080901

• Tipifarnib in the treatment of newly diagnosed acute myelogenous leukemia.

  Biologics : targets & therapy 20080901

• Tumorigenic activity and therapeutic inhibition of Rheb GTPase.

  Genes & development 20080815

• The FLT3 inhibitor PKC412 in combination with cytostatic drugs in vitro in acute myeloid leukemia.

  Cancer chemotherapy and pharmacology 20080801

• [Targeted therapy for locally advanced and/or metastatic bladder cancer].

  Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie 20080701

• Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.

  British journal of haematology 20080501

• Combining the farnesyltransferase inhibitor lonafarnib with paclitaxel results in enhanced growth inhibitory effects on human ovarian cancer models in vitro and in vivo.

  Gynecologic oncology 20080401

• Insulin-like growth factor-I receptor signaling pathway induces resistance to the apoptotic activities of SCH66336 (lonafarnib) through Akt/mammalian target of rapamycin-mediated increases in survivin expression.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20080301

• Therapeutic options for chronic myeloid leukemia: focus on imatinib (Glivec, Gleevectrade mark).

  Therapeutics and clinical risk management 20080201

• Exploring three-dimensional quantitative structural activity relationship (3D-QSAR) analysis of SCH 66336 (Sarasar) analogues of farnesyltransferase inhibitors.

  European journal of medicinal chemistry 20080101

• SCH66336, inhibitor of protein farnesylation, blocks signal transducer and activators of transcription 3 signaling in lung cancer and interacts with a small molecule inhibitor of epidermal growth factor receptor/human epidermal growth factor receptor 2.

  Anti-cancer drugs 20080101

• Farnesyl transferase inhibitors induce extended remissions in transgenic mice with mature B cell lymphomas.

  Molecular cancer 20080101

• Molecular targeted therapies for breast cancer treatment.

  Breast cancer research : BCR 20080101

• The RAS/mitogen activated protein (MAP) kinase pathway in melanoma biology and therapeutics.

  Biologics : targets & therapy 20071201

• Tipifarnib in the treatment of acute myeloid leukemia.

  Biologics : targets & therapy 20071201

• Effect of food on the pharmacokinetics of lonafarnib (SCH 66336) following single and multiple doses.

  International journal of clinical pharmacology and therapeutics 20071001

• Farnesyl transferase inhibitor resistance probed by target mutagenesis.

  Blood 20070915

• Farnesyltransferase inhibitors inhibit T-cell cytokine production at the posttranscriptional level.

  Blood 20070915

• Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib.

  Cancer 20070915

• Enhancement of the antitumor activity of tamoxifen and anastrozole by the farnesyltransferase inhibitor lonafarnib (SCH66336).

  Anti-cancer drugs 20070901

• The molecular genetics of breast cancer and targeted therapy.

  Biologics : targets & therapy 20070901

• Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: a Pediatric Brain Tumor Consortium Study.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20070720

• Farnesyltransferase inihibitors in hematologic malignancies.

  Blood reviews 20070701

• The farnesyltransferase inhibitor lonafarnib induces CCAAT/enhancer-binding protein homologous protein-dependent expression of death receptor 5, leading to induction of apoptosis in human cancer cells.

  The Journal of biological chemistry 20070629

• New agents for treatment of advanced transitional cell carcinoma.

  Annals of oncology : official journal of the European Society for Medical Oncology 20070501

• The farnesyl transferase inhibitor, tipifarnib, is a potent inhibitor of the MDR1 gene product, P-glycoprotein, and demonstrates significant cytotoxic synergism against human leukemia cell lines.

  Leukemia 20070401

• Farnesyl transferase inhibitors impair chromosomal maintenance in cell lines and human tumors by compromising CENP-E and CENP-F function.

  Molecular cancer therapeutics 20070401

• Inhibitors of the mevalonate pathway as potential therapeutic agents in multiple myeloma.

  Leukemia research 20070301

• Phase I study of the farnesyltransferase inhibitor lonafarnib with weekly paclitaxel in patients with solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20070115

• Clinical trials update: endocrine and biological therapy combinations in the treatment of breast cancer.

  Breast cancer research : BCR 20070101

• A generalized response surface model with varying relative potency for assessing drug interaction.

  Biometrics 20061201

• Identification of unstable metabolites of Lonafarnib using liquid chromatography-quadrupole time-of-flight mass spectrometry, stable isotope incorporation and ion source temperature alteration.

  Journal of mass spectrometry : JMS 20061101

• Combination therapy with aromatase inhibitors: the next era of breast cancer treatment?

  British journal of cancer 20060918

• Lonafarnib in cancer therapy.

  Expert opinion on investigational drugs 20060601

• Identification of human liver cytochrome P450 enzymes responsible for the metabolism of lonafarnib (Sarasar).

  Drug metabolism and disposition: the biological fate of chemicals 20060401

• [Farnesyl transferase inhibitors--a novel agent for breast cancer].

  Ai zheng = Aizheng = Chinese journal of cancer 20060401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060301

• Farnesyltransferase inhibitors in myelodysplastic syndrome.

  Current hematologic malignancy reports 20060301

• Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy.

  Cancer 20060115

• Identification of insulin-like growth factor binding protein-3 as a farnesyl transferase inhibitor SCH66336-induced negative regulator of angiogenesis in head and neck squamous cell carcinoma.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060115

• Myelodysplasia: when to treat and how.

  Best practice & research. Clinical haematology 20060101

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20060101

• The combination of the farnesyl transferase inhibitor lonafarnib and the proteasome inhibitor bortezomib induces synergistic apoptosis in human myeloma cells that is associated with down-regulation of p-AKT.

  Blood 20051215

• Microtubule interactions with chemically diverse stabilizing agents: thermodynamics of binding to the paclitaxel site predicts cytotoxicity.

  Chemistry & biology 20051201

• Hypoxia-inducible factor 1alpha and antiangiogenic activity of farnesyltransferase inhibitor SCH66336 in human aerodigestive tract cancer.

  Journal of the National Cancer Institute 20050907

• The farnesyl transferase inhibitor (FTI) SCH66336 (lonafarnib) inhibits Rheb farnesylation and mTOR signaling. Role in FTI enhancement of taxane and tamoxifen anti-tumor activity.

  The Journal of biological chemistry 20050902

• Development of farnesyl transferase inhibitors: a review.

  The oncologist 20050901

• [Molecular targeted therapy for malignant brain tumors].

  Nihon rinsho. Japanese journal of clinical medicine 20050901

• Characterization of a human carcinoma cell line selected for resistance to the farnesyl transferase inhibitor 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide (SCH66336).

  Molecular pharmacology 20050801

• Phase II study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in patients with taxane-refractory/resistant nonsmall cell lung carcinoma.

  Cancer 20050801

• Lonafarnib reduces the resistance of primitive quiescent CML cells to imatinib mesylate in vitro.

  Leukemia 20050701

• Farnesyltransferase inhibitor SCH66336 induces rapid phosphorylation of eukaryotic translation elongation factor 2 in head and neck squamous cell carcinoma cells.

  Cancer research 20050701

• Protein farnesyltransferase inhibitors exhibit potent antimalarial activity.

  Journal of medicinal chemistry 20050602

• Farnesyltransferase inhibitor SCH-66336 downregulates secretion of matrix proteinases and inhibits carcinoma cell migration.

  International journal of cancer 20050501

• Isoprenylation of intracellular proteins as a new target for the therapy of human neoplasms: preclinical and clinical implications.

  Current drug targets 20050501

• Farnesyltransferase inhibitors in myelodysplastic syndrome.

  Current hematology reports 20050501

• The synergistic combination of the farnesyl transferase inhibitor lonafarnib and paclitaxel enhances tubulin acetylation and requires a functional tubulin deacetylase.

  Cancer research 20050501

• Multicentre EORTC study 16997: feasibility and phase II trial of farnesyl transferase inhibitor & gemcitabine combination in salvage treatment of advanced urothelial tract cancers.

  European journal of cancer (Oxford, England : 1990) 20050501

• Design, synthesis, and activity of achiral analogs of 2-quinolones and indoles as non-thiol farnesyltransferase inhibitors.

  Bioorganic & medicinal chemistry letters 20050415

• Hit to Lead Success Stories--IBC Conference: Effective chemistry strategies for reducing attrition rates and speeding lead compounds into the pipeline. 31 January-1 February 2005, San Diego, CA, USA.

  IDrugs : the investigational drugs journal 20050301

• [Farnesyltransferase inhibitors: preliminary results in acute myeloid leukemia].

  Bulletin du cancer 20050301

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20050301

• The effect of the farnesyl protein transferase inhibitor SCH66336 on isoprenylation and signalling by the prostacyclin receptor.

  The Biochemical journal 20050215

• Hyperleukocytosis complicating lonafarnib treatment in patients with chronic myelomonocytic leukemia.

  Leukemia 20050201

• A multinomial Phase II study of lonafarnib (SCH 66336) in patients with refractory urothelial cancer.

  Urologic oncology 20050101

• Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasartrade mark, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry.

  Rapid communications in mass spectrometry : RCM 20050101

• Synthesis of 5-bromopyridyl-2-magnesium chloride and its application in the synthesis of functionalized pyridines.

  Organic letters 20041223

• Farnesyl protein transferase inhibitors targeting the catalytic zinc for enhanced binding.

  Bioorganic & medicinal chemistry letters 20041206

• Bridgehead modification of trihalocycloheptabenzopyridine leads to a potent farnesyl protein transferase inhibitor with improved oral metabolic stability.

  Bioorganic & medicinal chemistry letters 20041206

• Design, synthesis, and activity of 4-quinolone and pyridone compounds as nonthiol-containing farnesyltransferase inhibitors.

  Bioorganic & medicinal chemistry letters 20041101

• The farnesyltransferase inhibitor Lonafarnib induces growth arrest or apoptosis of human lung cancer cells without downregulation of Akt.

  Cancer biology & therapy 20041101

• Clinical activity of farnesyl transferase inhibitors in hematologic malignancies: possible mechanisms of action.

  Leukemia & lymphoma 20041101

• Farnesyltransferase inhibition: who are the Aktors?

  Cancer biology & therapy 20041101

• Effects of insulin-like growth factor binding protein-3 and farnesyltransferase inhibitor SCH66336 on Akt expression and apoptosis in non-small-cell lung cancer cells.

  Journal of the National Cancer Institute 20041020

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040901

• Solution phase parallel synthesis and evaluation of MAPK inhibitory activities of close structural analogues of a Ras pathway modulator.

  Bioorganic & medicinal chemistry letters 20040802

• Farnesyltransferase inhibitors as anticancer agents: critical crossroads.

  Current opinion in drug discovery & development 20040701

• Protein farnesyltransferase inhibitor (SCH 66336) abolishes NF-kappaB activation induced by various carcinogens and inflammatory stimuli leading to suppression of NF-kappaB-regulated gene expression and up-regulation of apoptosis.

  The Journal of biological chemistry 20040618

• Phase I study of the farnesyltransferase inhibitor lonafarnib with paclitaxel in solid tumors.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20040501

• Novel agents and incremental advances in the treatment of head and neck cancer.

  Seminars in oncology 20040401

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20040301

• In vitro study of farnesyltransferase inhibitor SCH 66336, in combination with chemotherapy and radiation, in non-small cell lung cancer cell lines.

  Oncology reports 20040201

• Design, synthesis, and biological activity of 4-[(4-cyano-2-arylbenzyloxy)-(3-methyl-3H-imidazol-4-yl)methyl]benzonitriles as potent and selective farnesyltransferase inhibitors.

  Journal of medicinal chemistry 20040129

• Cancer treatment with kinase inhibitors: what have we learnt from imatinib?

  British journal of cancer 20040112

• A farnesyltransferase inhibitor increases survival of mice with very advanced stage acute lymphoblastic leukemia/lymphoma caused by P190 Bcr/Abl.

  Leukemia 20040101

• [Molecular pathogenesis of chronic myeloid leukemia and tyrosine kinase inhibitor].

  [Rinsho ketsueki] The Japanese journal of clinical hematology 20040101

• New targets for therapy in breast cancer: farnesyltransferase inhibitors.

  Breast cancer research : BCR 20040101

• [Ras signaling pathway as a target for farnesyltransferase inhibitors--a new, promising prospects in the treatment for malignant disorders].

  Wiadomosci lekarskie (Warsaw, Poland : 1960) 20040101

• The farnesyl protein transferase inhibitor lonafarnib (SCH66336) is an inhibitor of multidrug resistance proteins 1 and 2.

  Chemotherapy 20031201

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20031101

• Farnesyltransferase inhibitors and their potential in the treatment of breast carcinoma.

  Seminars in oncology 20031001

• Implication of protein kinase B/Akt and Bcl-2/Bcl-XL suppression by the farnesyl transferase inhibitor SCH66336 in apoptosis induction in squamous carcinoma cells.

  Cancer research 20030815

• Farnesyltransferase inhibitors in acute myeloid leukemia and myelodysplastic syndromes.

  Clinical lymphoma 20030801

• High-performance liquid chromatography-atmospheric pressure photoionization/tandem mass spectrometric analysis for small molecules in plasma.

  Analytical chemistry 20030701

• A novel enantioselective alkylation and its application to the synthesis of an anticancer agent.

  The Journal of organic chemistry 20030613

• Farnesyl transferase inhibitor SCH66336 is cytostatic, pro-apoptotic and enhances chemosensitivity to cisplatin in melanoma cells.

  International journal of cancer 20030610

• Farnesyl transferase inhibitors in clinical development.

  Expert opinion on investigational drugs 20030601

• Novel and selective imidazole-containing biphenyl inhibitors of protein farnesyltransferase.

  Bioorganic & medicinal chemistry letters 20030407

• Preclinical and clinical evaluation of farnesyltransferase inhibitors.

  Current oncology reports 20030301

• Apoptotic synergism between STI571 and the farnesyl transferase inhibitor SCH66336 on an imatinib-sensitive cell line.

  Blood 20030301

• Farnesyl transferase inhibitors in the treatment of breast cancer.

  Expert opinion on investigational drugs 20030301

• Efficacy of SCH66336, a farnesyl transferase inhibitor, in conjunction with imatinib against BCR-ABL-positive cells.

  Molecular cancer therapeutics 20030301

• Overcoming resistance to imatinib by combining targeted agents.

  Molecular cancer therapeutics 20030301

• Trihalobenzocycloheptapyridine analogues of Sch 66336 as potent inhibitors of farnesyl protein transferase.

  Bioorganic & medicinal chemistry 20030102

• Targeting RAS signalling pathways in cancer therapy.

  Nature reviews. Cancer 20030101

• Sch-66336 (sarasar) and other benzocycloheptapyridyl farnesyl protein transferase inhibitors: discovery, biology and clinical observations.

  Current topics in medicinal chemistry 20030101

• Farnesyltransferase inhibitors--a novel approach in the treatment of advanced pancreatic carcinomas.

  Anticancer research 20030101

• Phase I and pharmacological study of the oral farnesyltransferase inhibitor SCH 66336 given once daily to patients with advanced solid tumours.

  European journal of cancer (Oxford, England : 1990) 20021101

• Farnesyl transferase inhibitors as anticancer agents.

  European journal of cancer (Oxford, England : 1990) 20020901

• Farnesyl transferase inhibitors: a major breakthrough in anticancer therapy? Naples, 12 April 2002.

  Anti-cancer drugs 20020901

• Gateways to Clinical Trials.

  Methods and findings in experimental and clinical pharmacology 20020901

• Exploring the role of bromine at C(10) of (+)-4-[2-[4-(8-chloro-3,10-dibromo- 6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]pyridin-11(R)-yl)-1-piperidinyl]-2- oxoethyl]-1-piperidinecarboxamide (Sch-66336): the discovery of indolocycloheptapyridine inhibitors of farnesyl protein transferase.

  Journal of medicinal chemistry 20020829

• Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336.

  Blood 20020801

• A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.

  Annals of oncology : official journal of the European Society for Medical Oncology 20020701

• Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.

  Experimental cell research 20020215

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20020101

• Agents targeting ras signaling pathway.

  Current pharmaceutical design 20020101

• Farnesyltransferase inhibitors in breast cancer therapy.

  Cancer investigation 20020101

• An anion-induced regio- and chemoselective acylation and its application to the synthesis of an anticancer agent.

  Organic letters 20011115

• Current status of clinical trials of farnesyltransferase inhibitors.

  Current opinion in oncology 20011101

• The farnesyl protein transferase inhibitor SCH66336 is a potent inhibitor of MDR1 product P-glycoprotein.

  Cancer research 20011015

• Farnesyl protein transferase inhibition: a novel approach to anti-tumor therapy. the discovery and development of SCH 66336.

  Current medicinal chemistry 20011001

• Farnesyltransferase inhibitors.

  Seminars in oncology 20011001

• Isotype-specific Ras.GTP-levels predict the efficacy of farnesyl transferase inhibitors against human astrocytomas regardless of Ras mutational status.

  Cancer research 20010601

• Synergy of the protein farnesyltransferase inhibitor SCH66336 and cisplatin in human cancer cell lines.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20010501

• Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336.

  Blood 20010301

• Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.

  Blood 20010301

• Phase I and pharmacokinetic study of the oral farnesyl transferase inhibitor SCH 66336 given twice daily to patients with advanced solid tumors.

  Journal of clinical oncology : official journal of the American Society of Clinical Oncology 20010215

• The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.

  Experimental cell research 20010101

• Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.

  Cancer research 19981101